Baxter International Inc

BAX is in a Stage 4 decline following a decisive support failure below the 50-day SMA and key support zone, confirming sustained selling pressure. Short-term momentum is bearish with price below the 9- and 20-day EMAs and no oversold exhaustion evident. The medium-term bias remains bearish with no mean-reversion eligibility. Execution favors immediate Sell Now on continuation or any bounce into the 9/20-day EMAs or the broken support cluster.

• ↑Q2 2026 sales reached $3 B, +5% YoY both reported and organic.
• ↑Free cash flow of $181 M helps reduce leverage toward ~3x by 2026.
• ↓Novum pump shipment hold limits revenue until regulatory clearance.